← Back to Search

Radioactive Agent

Catheterization for Prostate Cancer

Q: Are there specific eligibility requirements to participate in this experiment?

Only men with <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> that are between 18-80 years old can be a part of this study--of which there are only 5 slots available.

Q: For what reasons is Catheterization commonly used?

Tumor antigens are most often treated with Catheterization, though this method is also useful for treating metastasis, positron emission tomography, and <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a>.

Q: Are there any other ongoing or previous research projects that have used Catheterization?

There are a total of 13 clinical studies being conducted that focus on catheterization with one of those trials currently in Phase 3. The majority of these research projects are taking place in Rochester, <a href="https://www.withpower.com/clinical-trials/minnesota">Minnesota</a>; however, there are 17 clinical locations across the United States running these types of trials.

Q: Does the age limit for participation in this trial extend past 80 years old?

Eligibility requirements for this trial state that potential participants must be between 18-80 years old. There are 77 other clinical trials underway for individuals below 18 and 1,377 for seniors above 65.

Phase < 1

Waitlist Available

Led By Ryan Kohlbrenner

Research Sponsored by Ryan Kohlbrenner, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 and from day 2 up to day 15 (2 days total)

Awards & highlights

Study Summary

This trial will use PET to compare the prostate uptake of 68Ga-PSMA-11 delivered intra-arterially to that of the same agent delivered intravenously.

Eligible Conditions

Prostate Cancer
Prostate Adenocarcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 and from day 2 up to day 15 (2 days total)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 and from day 2 up to day 15 (2 days total)

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 and from day 2 up to day 15 (2 days total) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum standardized uptake value (SUVmax)

Secondary outcome measures

Comparison of Area under the curve (AUC)

Comparison of Mass dose at saturation

Comparison of Mean SUV (SUVmean)

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ga-PSMA-11, PET/CT, Angiogram, and Prostatic Arterial CatheterizationExperimental Treatment4 Interventions

Patients receive 68Ga-PSMA-11 IV over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after on day 1. One to 14 days later, patients undergo pelvic angiogram and prostatic arterial catheterization. Patients then receive 68Ga-PSMA-11 IA over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Angiogram

2021

Completed Early Phase 1

~10

Catheterization

2015

Completed Early Phase 1

~440

Gallium Ga-labeled PSMA-11

2021

Completed Early Phase 1

~10

Positron Emission Tomography

2008

Completed Phase 2

~2240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ryan Kohlbrenner, MDLead Sponsor

Radiological Society of North AmericaOTHER

25 Previous Clinical Trials

1,814 Total Patients Enrolled

2 Trials studying Prostate Cancer

105 Patients Enrolled for Prostate Cancer

Ryan KohlbrennerPrincipal InvestigatorUniversity of California, San Francisco

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there specific eligibility requirements to participate in this experiment?

"Only men with prostate cancer that are between 18-80 years old can be a part of this study--of which there are only 5 slots available."

Answered by AI

For what reasons is Catheterization commonly used?

"Tumor antigens are most often treated with Catheterization, though this method is also useful for treating metastasis, positron emission tomography, and prostate cancer."

Answered by AI

Are there any other ongoing or previous research projects that have used Catheterization?

"There are a total of 13 clinical studies being conducted that focus on catheterization with one of those trials currently in Phase 3. The majority of these research projects are taking place in Rochester, Minnesota; however, there are 17 clinical locations across the United States running these types of trials."

Answered by AI

Does the age limit for participation in this trial extend past 80 years old?

"Eligibility requirements for this trial state that potential participants must be between 18-80 years old. There are 77 other clinical trials underway for individuals below 18 and 1,377 for seniors above 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Ryan Kohlbrenner, MD 2021. "Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04976257.